Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | JAK1 | P23458 | 3/20 | 0.32 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30882773 | 1.00 | LMNA (0.35) | LMNAADORA2APTGER4MKNK2JAK2 | |
| SCHEMBL29924291 | 0.87 | PTGER4 (0.35) | PTGER4PPARG | |
| SCHEMBL27110991 | 0.81 | ACSS2 (0.41) | ADORA2APPARG | |
| SCHEMBL30269574 | 0.81 | ACSS2 (0.41) | ADORA2APPARG | |
| SCHEMBL29825592 | 0.81 | GLP1R (0.32) | JAK2JAK1 | |
| SCHEMBL31425059 | 0.81 | GLP1R (0.32) | JAK2JAK1 | |
| SCHEMBL23286903 | 0.81 | GLP1R (0.32) | JAK2JAK1 | |
| SCHEMBL30259333 | 0.78 | MKNK2 (0.35) | LMNAPTGER4MKNK2JAK2JAK1 | |
| SCHEMBL25004893 | 0.77 | CYP1A2 (0.38) | ADORA2A | |
| SCHEMBL29924769 | 0.77 | CYP1A2 (0.38) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360109-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2024-10-31 | — | — | US | disclosed |
| EP-4382525-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-117751110-A | Cycloolefin derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023011539-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360109-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | CYP51A1, FAR1, CYP46A1 | LMNA 2309/4885ADORA2A 4191/4885PTGER4 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.